Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Benzinga · 1d ago
Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.